CSF1R and tenosynovial giant cell tumor, diffuse type: Early phase clinical trials show promising results of CSF1R inhibitors in tenosynovial giant cell tumours (TGCT), advanced solid tumours, pancreatic cancer, and gastrointestinal stromal tumour [27–30].